Astex Therapeutics Limited

Janssen Pharmaceutica Nv

Janssen Biotech, Inc.

Pascal Ghislain André Bonnet

Eddy Jean Edgard Freyne

Christopher William Murray

Valerio Berdini

Gordon Saxty

Werner Constant Johan Embrechts

Berthold Wroblowski

Alexandra Papanikos

Lieven Meerpoel

Patrick René Angibaud

Isabelle Noëlle Constance Pilatte

Laurence Anne Mevellec

Timothy Pietro Suren Perera

Gilbert Besong

Steven John Woodhead

Rhalid Akkari

Christopher Norbert Johnson

Kristof Van Emelen

Olivier Alexis Georges Querolle

Jean Fernand Armand Lacrampe

David Charles Rees

Ronaldus Arnodus Hendrika Joseph Gilissen

Christopher Charles Frederick Hamlett

Elisabeth Thérèse Jeanne Pasquier

Michael Reader

Marc Gustaaf Celine Verdonck

Johan Erwin Edmond Weerts

Janet Davis

Jiajian Liu

Christine Parmenter

Tom Cornelis Hortense Govaerts

Gaston Stanislas Marcella Diels

Peter Ten Holte

Peter Jacobus Johannes Antonius Buijnsters

Yannick Aimé Eddy Ligny

Peter Jacobus Johannes Buijnsters

Oliver Alexis Georges Querolle

Thierry Andre Regis Grand-Perret

Gilbert Ebai Besong

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Pyrazolyl quinoxaline kinase inhibitors

The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

Differentiation of pluripotent stem cells

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. 

The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy

The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y, m, n, R; X; X; R; X; X; R; and Rhave the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

4-aryl-2-anilino-pyrimidines

The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

Pyrrolopyrimidines

Growing community of inventors

Berchem, Belgium

Pascal Ghislain André Bonnet